Maybe there weren’t any PR people involved with the early beginnings of this company, but Shakespeare taught us there is nothing substantial in but a name; the company is doing well and you should consider it.
I know I am. I might even buy some, but not sure yet.
Let’s look at its technical action. It went public July 25 and formed a square box base (four weeks in length, we don’t count that first up week) which it broke out of today (yesterday, I’m writing this post at 4am) on what appears to be nice volume (it’s too young to have a 50 day average volume to compare it to). The buy point, where the green arrow points to, is $20.58.
I’ve often missed such early break outs, which I admit is part of the enchantment of this rocky-mountain/mid-western stock.
The positives are up first, because that’s how I like to start. It is a young company, having only gone public this July 25, and it’s exceptionally young in the potential life of a retail chain. It has only 55 locations with hopes to grow some day to 1,100.
If that kind of growth happened in a short time frame, bocu-bucks could be yours. I don’t know how to spell that but it’s fun to say.
It’s in a hot group that includes the 800 pound organic gorilla, Whole Foods. It also includes a stock that broke out recently (and is still in a buy zone), The Fresh Market (TFM). Organic foods and the like are trendy right now, and it’s more than a fad. There seems to be serious money out there all over the country for such products.
Here is a quick description of NGVC (I don’t know what I like less, the company name or the ticker symbol) as provided by E-trade: “The Company operates within the natural products retail industry. The Company offers products and brands, including a selection of natural and organic food, dietary supplements, body care products, pet care products and books.”
The “and books” part is weird, but maybe it draws foot traffic, I don’t know. The rest of it is certainly in demand.
NGVC has a 97 EPS rating, an “A” SMR rating and a 95 Composite rating. These, as usual, are all IBD proprietary ratings you can find in their daily paper. And these are most excellent ratings at that. It even sports an 89 relative strength rating.
The past three quarters sport from 100% to 167% earnings growth and 23% to 28% sales growth. The quarters prior to this growth were negative to zero and I have yet to understand why.
What’s more important is where this company appears to be headed. This year the stock is expected to have 119% earnings growth and next year’s earnings growth is projected to be 34%. These are all very nice numbers, yes indeedy.
Return on equity is a healthy 28%, although it also carries a 119% debt load, putting a slight damper on that ROE number.
It’s unclear how many funds own the stock at this point but management owns 65% of the stock, a terrific number to see. It means those who run the show stand to gain the better the stock performs.
Also, according to E-trade’s research, it looks like management took on some additional shares recently. The company’s CFO, Sandra Buffa, un persona mui importante, (Spanish lingo for very important officer of the company), bought 4,000 shares at $15 per share, as reported July 16 (she bought this before it hit the stock exchange shelves). What is that – that’s $60,000, not huge cash, but not chump change either.
Also one Anthony Andueza picked up $9,700 worth of stock. OK, I admit, that one’s a little anemic, and I honestly don’t know who this guy is or what he does for the company, but at least he’s adding to his already hefty amount of shares, still worth taking notice of.
And now some of the negatives. There aren’t that many from my perspective. The ones that matter to me are that I don’t know how many funds own the company, as mentioned above. And tributary to that thought is that NGVC (hate typing that) has a market capitalization of under $500 million, which is too small for a number of mutual funds and institutional buyers to consider. This will change if the price appreciates and the company grows.
Also, information is slightly hard to come by on this small and new issue, not unusual, but pesky. Facebook and other similar companies get all the attention. It could work for you as the company becomes more known and people pile on, but in the meanwhile it makes research challenging.
If you check Yahoo’s estimates, you’ll see none, and CNBC and E-trade both suggest a big earnings growth quarter ahead but looks like a flat quarter after that. However, my experience with young and little followed companies is that sometimes these estimates aren’t reliable. It’s worth digging deeper on.
It is also apparently too young a stock (I’m guessing here) to have an IBD accumulation/distribution rating which measures buying or selling in a stock. But the up/down volume on the stock is an eye-popping 7.2, but something tells me this number is highly inflated by the first day of trading, which provides more challenges to gauging a stock’s worthiness.
And to reiterate, it has 113% debt.
All in all, the worst part about this stock is the lack of information on it. That and its not very artful name.










